Analyst Reco. Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
65.19 ^USD	-0.58%		-1.17%	+3.81%

May. 08	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	Apr. 25	MT
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	Mar. 21	MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	Mar. 12	MT
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	Feb. 28	MT
Mizuho Initiates Vaxcyte With Buy Rating, Price Target is $69	Dec. 07	MT
TD Cowen Starts Vaxcyte at Outperform	23-04-18	MT
BofA Securities Adjusts Price Target on Vaxcyte to $68 From $63, Keeps Buy Rating	23-04-18	MT
Guggenheim Adjusts Price Target on Vaxcyte to $65 From $66, Maintains Buy Rating	23-02-28	MT
Needham Adjusts Price Target on Vaxcyte to $58 From $52, Maintains Buy Rating	23-01-03	MT
SVB Securities Initiates Vaxcyte With Outperform Rating, Sets Price Target at $60	22-12-16	MT
Guggenheim Initiates Vaxcyte at Buy With $66 Price Target	22-12-15	MT
BTIG Starts Vaxcyte at Buy With $69 Price Target	22-11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW